Skip to main content
PTPI logo

Petros Pharmaceuticals, Inc. (PTPI) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.0021 -$0.0002 (-8.70%)
P/E Ratio: 0.00| Vol: 189.2K| 52-wk range: $0.001825 – $0.016

P/E 0.00 means the share price is 0.00 times one year of earnings per share. Beta 1.66: the stock has moved about 66% more than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Petros Pharmaceuticals, Inc. (PTPI) trades at $0.0021. Petros Pharmaceuticals, Inc. focuses on the development and commercialization of men's health therapeutics, primarily addressing erectile dysfunction and Peyronie's disease. Sector: Healthcare.

Price as of · Last analyzed: Mar 16, 2026
Petros Pharmaceuticals, Inc. focuses on the development and commercialization of men's health therapeutics, primarily addressing erectile dysfunction and Peyronie's disease. Their lead product is Stendra, a prescription medication for erectile dysfunction, and they are developing H100 for Peyronie's disease.

Analyst Coverage for PTPI: PTPI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • CCM · Concord Medical Services Holdings Limited · 26 /100
  • CELU · Celularity Inc. · 21 /100
  • SXTC · China SXT Pharmaceuticals, Inc. · 19 /100

See all scored stocks →

Petros Pharmaceuticals, Inc. (PTPI) Healthcare & Pipeline Overview

CEOFady Boctor
Employees3
HeadquartersNew York City, US
IPO Year2020

Petros Pharmaceuticals, Inc. is a pharmaceutical company specializing in men's health, particularly erectile dysfunction (ED) and Peyronie's disease. Their key product, Stendra, targets ED, while H100 is under development for Peyronie's. The company operates within the specialty and generic drug manufacturing sector, focusing on unmet needs in men's health.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 16, 2026

What Is the Investment Thesis for PTPI?

AI-written as of Mar 16, 2026 — figures and tone reflect the data available then, not today's score.

Petros Pharmaceuticals presents a focused approach to men's health, primarily through Stendra for erectile dysfunction and the investigational drug H100 for Peyronie's disease. With a gross margin of 63.5%, the company demonstrates potential for profitability, although the current profit margin is -968.2%. Key to the investment thesis is the successful commercialization of H100, which could address a significant unmet need. The company's high beta of 1.66 suggests higher volatility compared to the market. Upcoming catalysts include clinical trial updates for H100 and potential partnerships to expand market reach. Investors should monitor the company's ability to manage its expenses and achieve profitability.

Based on FMP financials and quantitative analysis

PTPI Key Highlights

AI-written as of Mar 16, 2026 — figures and tone reflect the data available then, not today's score.

Gross Margin of 63.5% indicates strong potential for profitability on sales.

  • Focus on men's health therapeutics provides a niche market opportunity.
  • Development of H100 for Peyronie's disease addresses an unmet medical need.
  • Stendra, a PDE-5 inhibitor, is the company's key commercialized product for erectile dysfunction.
  • Market Capitalization of $0.00B reflects the company's current small size and potential for growth.

Who Are PTPI's Competitors?

PTPI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
CCM Concord Medical Services Holdings Limited $3.41 -5.36% $14.8M —
CELU Celularity Inc. $0.47 -3.15% $15.2M —
HEPA Hepion Pharmaceuticals, Inc. $0.10 +4.78% $11.8M —
LIXT Lixte Biotechnology Holdings, Inc. $7.21 -6.00% $89.1M —
SXTC China SXT Pharmaceuticals, Inc. $2.59 -8.48% —
YCBD cbdMD, Inc. $0.38 +1.42% $5.10M —
AKAN Akanda Corp. $3.43 -14.89% $9.05M —
QNTM Quantum BioPharma Ltd. $1.42 -6.58% $9.13M 30 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PTPI's Key Strengths?

Focus on men's health therapeutics.

  • Commercialized product (Stendra) generating revenue.
  • Development of H100 addressing an unmet need.
  • Established distribution network for Stendra.

What Are PTPI's Weaknesses?

Limited product portfolio.

  • High operating expenses.
  • Dependence on Stendra for revenue.
  • Negative profit margin.

What Are the Key Risks for PTPI?

Financial-distress signal — its Altman Z-Score of -47.46 sits in the distress zone (elevated bankruptcy risk).

  • Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 6 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
  • Competition from established pharmaceutical companies with greater resources.
  • Regulatory setbacks in the approval process for H100.
  • Dependence on Stendra for a significant portion of revenue.
  • Fluctuations in market demand for erectile dysfunction treatments.

What Threats Does PTPI Face?

  • Competition from established pharmaceutical companies.
  • Regulatory hurdles for new drug approvals.
  • Patent expiration for key products.
  • Economic downturn affecting healthcare spending.

What Are PTPI's Competitive Advantages?

  • Patent protection for H100 provides a competitive advantage in the Peyronie's disease market.
  • Established brand recognition for Stendra in the erectile dysfunction market.
  • Focus on a specific niche within the pharmaceutical industry (men's health).
  • Proprietary formulations and delivery systems for its products.

What Does PTPI Do?

Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to addressing unmet medical needs in men's health. The company's primary focus is on the commercialization and development of therapeutics for conditions such as erectile dysfunction (ED) and Peyronie's disease. Petros Pharmaceuticals' lead product is Stendra, a PDE-5 inhibitor prescription medication used for the treatment of ED. Stendra is a key revenue driver for the company, offering a treatment option for men experiencing erectile dysfunction. In addition to Stendra, Petros Pharmaceuticals is developing H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. Peyronie's disease is a condition characterized by the development of fibrous plaques in the penis, leading to pain and curvature during erection. H100 represents a potential novel treatment option for this condition. The company also markets vacuum erection device products, expanding its portfolio of solutions for ED. Petros Pharmaceuticals, Inc. is based in New York, New York, and manages its operations with a team of 18 employees.

What Products and Services Does PTPI Offer?

  • Develop and commercialize Stendra, a prescription medication for erectile dysfunction (ED).
  • Develop H100, a topical formulation candidate for the treatment of acute Peyronie's disease.
  • Market vacuum erection device products for ED.
  • Focus on addressing unmet medical needs in men's health.
  • Conduct clinical trials to evaluate the safety and efficacy of H100.
  • Seek regulatory approvals for new products and indications.

How Does PTPI Make Money?

  • Develop, market, and sell pharmaceutical products focused on men's health.
  • Generate revenue through sales of Stendra and vacuum erection devices.
  • Invest in research and development to expand product pipeline.
  • Seek partnerships and collaborations to expand market reach and product offerings.

What Industry Does PTPI Operate In?

Petros Pharmaceuticals operates within the specialty and generic drug manufacturing industry, a segment of the broader healthcare sector. The market for men's health therapeutics is driven by factors such as aging populations, changing lifestyles, and increased awareness of medical conditions. The competitive landscape includes companies focusing on similar therapeutic areas, as well as larger pharmaceutical companies with broader product portfolios. Petros Pharmaceuticals' focus on specific men's health conditions like ED and Peyronie's disease allows it to potentially capture a niche market share.

Who Are PTPI's Key Customers?

  • Men experiencing erectile dysfunction (ED).
  • Men diagnosed with Peyronie's disease.
  • Healthcare providers who prescribe and recommend Petros Pharmaceuticals' products.
  • Pharmacies and distributors that stock and sell Petros Pharmaceuticals' products.
Model self-rating on this text: 81% (not a measure of the evidence) Updated: Mar 16, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● No usable price
  • ● No filing on record
  • ● No analyst coverage

Insider Activity

4 transactions · 0 purchases, 0 sales, 4 other transactions · 4 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Jun 5, 2026. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

P/E 0.0

Key Financial Metrics

Return on assets is -90.3%, showing how much profit it generates from its asset base. A current ratio of 1.25 indicates the company holds enough short-term assets to cover its near-term obligations.

F-Score 0/9

Financial Health

Petros Pharmaceuticals, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -47.46 places it in the distress zone, a signal of elevated financial risk.

2/6 beats

Earnings Track Record

Petros Pharmaceuticals, Inc. has missed Wall Street's EPS estimate in 4 of its last 6 reported quarters — a mixed record worth weighing. Reported results have landed about 1565.6% below estimates on average.

FY2026 est

Forward Outlook

Wall Street analysts project Petros Pharmaceuticals, Inc. revenue of about $11.0M for fiscal 2026, with EPS near $-27.50.

Company Profile

Petros Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Fady Boctor. PTPI has traded publicly since 2020.

PTPI Latest News

No recent news available for PTPI.

PTPI Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PTPI.

Price Targets

Wall Street price target analysis for PTPI.

PTPI MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PTPI; grades run from A+ (80-100) to F (below 30).

Leadership: Fady Boctor

CEO

Fady Boctor serves as the Chief Executive Officer of Petros Pharmaceuticals, Inc. His background includes extensive experience in the pharmaceutical industry, with a focus on commercialization and business development. He has held leadership positions at various pharmaceutical companies, where he was responsible for driving revenue growth and expanding market share. Boctor's expertise lies in developing and executing strategic plans, managing cross-functional teams, and building strong relationships with key stakeholders.

Track Record: Since assuming the role of CEO, Fady Boctor has focused on streamlining operations and maximizing the commercial potential of Stendra. He has also overseen the development of H100 and the expansion of the company's product pipeline. Under his leadership, Petros Pharmaceuticals has strengthened its market presence and forged strategic partnerships to drive growth.

PTPI OTC Market Information

PTPI trades on the OTC Other market tier of OTC Markets.

  • OTC Tier: OTC Other

Petros Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered

What do analysts say about PTPI stock?

Generally, analysts will assess the company's financial performance, product pipeline, and market opportunities to determine a fair valuation. Key metrics to watch include revenue growth, gross margin, and progress in clinical trials for H100. Investors should conduct their own due diligence and consider their risk tolerance before making any investment decisions.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Financial data is limited, impacting the depth of analysis.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives